Publication

Publications: 2003-2008: R Molina

  1. Molina R,  Filella X, Alicarte J, Zanon G, Pahisa J, Muñoz M, Farrus B, Ballesta AM. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003; 23:1035-1042. 
  2. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Muñoz M, Farrus B, Ballesta AM. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003; 23:1043-1050.

  3. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JMG, Filella X, Gornet TG, Hoff T, Jäger W, Van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I. Clinical evaluation of the Elecsys CA 15.3 test in breast cancer patients. Clin lab 2003; 49:15-24.

  4. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J,  Viladiu P. Tumor markers (CEA, CA 125, CYFRA 21,1, SCC and NSE) in NSCLC patients as an aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors. Tumor Biol 2003; 24:209-218.

  5. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torné A, Rovirosa A, Mellado B, Ordi J, Puig-Tintore LM, Alicarte J, Biete A, Iglesias J. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol 2003; 24:109-164.

  6. Mas S, Laso N, Lafuente MJ, Lafuente A, Molina R, Ballesta A, Ascaso C, Zheng S, Wiencke JK. Cancer, genes and catechol estrogen metabolites. Int J Clin Oncol 2003; 8: 65-66.

  7. Miret C, Molina R, Filella X, Garcia-Carrasco M, Claver G, Ingelmo M, Ballesta A, Font J. Relationship of p53 with other oncogenes, cytokines and systemic lupus erithematosus activity. Tumor Biol 2003; 24:185-188.

  8. Molina R, Alicarte J, Auge JM, Filella X, Viñolas N, Ballesta AM. Pro-gastrin releasing peptide (ProGRP) in patients with benign and malignant diseases. Tumor Biol 2004; 25: 56-61.

  9. Laso N, Mas S, Lafuente MJ, Casterad X, Trias M, Ballesta A, Molina R, Salas J, Ascaso C, Zheng S, Wiencke JK, Lafuente A. Decrease in specific micronutrient Intake in colorectal cancer patients with tumor presenting ki-ras mutation. Anticancer Res 2004; 24:2011-2020.

  10. Filella X, Truhán D, Alcover J, Quinto Ll, Molina R, Luque P, Coca F, Ballesta AM. Comparison of several combinations of free complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. Urology 2004; 63:1100-1104.

  11. Molina R, Filella X, Auge JM. ProGRP: A New Biomarker for Small Cell Lung Cancer. Clin Biochem 2004; 37:505-511.

  12. Reguart N, Viñolas N, Casas F, Gimferrer JM, Agusti C, Molina R, Martin-Richard M, Sanchez Reyes A, Gascon P. Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung Cancer 2004; 45: 67-75.

  13. Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Marquez A, Barreiro E, Borras J, Molina R, Viladiu P. Factors influencing survival in a prospective cohort of patients with Non-small cell lung cancer: An Updated assessment. Clin Oncol 2004:583-584 (Carta).

  14. Filella X, Truhán D, Alcover J, Gutierrez R, Molina R, Coca F, Ballesta AM. Complexed Prostate-specific antigen for the detection of Prostate Cancer. Anticancer Res 2004; 24:4281-4286.

  15. Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM. Pro-Gastrin-Releasing peptide (ProGRP) in patients with benign and malignant diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 2005; 25:1773-1778.

  16. Molina R, Filella X, Auge JM, Bosch E, Torne A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A. CYFRA 21.1 in patients cervical cancer: comparison with SCC and CEA. Anticancer Res 2005; 25:1765-1772.

  17. Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumor Biol 2005; 51:219-222.

  18. Domingo J, Molina R, Castel T, Montagut C, Puig S, Conill C, Marti R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B. Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon. Comparison with tyrosinase RT-PCR. Oncology 2005; 68:341-349.

  19. Nadal C, Maurel J, Gallego R, Castells A, Longaron R, Marmol M, Sanz S, Molina R, Martin-Richard M, Gascon P. Fass/Fasls ratio: a marker of oxiplantin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 2005; 11:4770-4774.

  20. Laso N, Mas, S, Lafuente MJ, Llobet JM, Molina R, Ballesta A, Kensler TW, Lafuente A. Induction of NAD (P)H Quinone Oxidoreductase by vegetables widely consumed in Catalonia, Spain. Nutrition and Cancer-An Int J 2005; 52:49-58.

  21. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Döletormos G, Stieber P. Tumor Markers in Breast Cancer. European Group on Tumor Markers Recommendations. Tumor Biol 2005; 26:281-293.

  22. Mas S, Crescenti A, Vidal-Taboada JM, Bergoñon S, Cuevillas F, Laso N, Molina R, Ballesta A, Lafuente A. Simultaneous genotyping of CYP2C9*2, *3, and 5’ flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extensión análisis. EurJ Clin Pharmacol 2005; 61:635-641.

  23. Auge JM, Molina R, Filella X, Bosch E, Gonzalez Cao M, Puig S, Malvehy J, Castel T, Ballesta AM. S-100B and MIA in advanced Melanoma in relation to prognostic factors. Anticancer Res 2005; 25:1779-1782.

  24. Trape J, Morales C, Molina R, Fililla X, Marcos JM, Salinas R, Franquesa J. Vascular endotelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Lab Invest 2006; 66:261-268.

  25. Mas S, Lafuente MJ, CrescentiA, Trias M, Ballesta A, Molina R, Zheng S, Wiencke JK, Lafuente A. Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16ink4alfa, p14ARF and hMLH1. Anticancer Res 2007; 27:1151-1156.

  26. Gonzalez Cao M, Auge JM, Molina R, Marti R, Carrea C, Castel T, Vilella R, Conill C, Sanchez M, Malvehy J, Puig S. Melanoma Inhibotory Activity Protein (MIA), Beta-2 microglobulin and Lactate Dehydrogenase (LDH) in Metastatic Melanoma. Anticancer Res 2007; 27:595-600.

  27. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Auge JM, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum Matrix Metalloprotease 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007; 121:1066-1071.

  28. Domingo-Domenech J,  Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggresive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.  Ann Oncol 2008; 19(2):269-275.